KETAMINE NASAL SPRAY IN NORWAY: ESKETAMINE (SPRAVATO) GUIDE
INTRODUCTION: THE RISE OF ESKETAMINE IN MENTAL HEALTH CARE
KETAMINE NASAL SPRAY IN NORWAY: ESKETAMINE (SPRAVATO) GUIDE. Mental health professionals worldwide have taken a growing interest in Esketamine, a fast-acting treatment delivered as a nasal spray. Marketed under the brand name Spravato, this drug specifically treats treatment-resistant depression (TRD). But how accessible is Esketamine in Norway? What should patients know before seeking this option?
This guide explores the key facts about Esketamine nasal spray, including how it works, its approval status in Norway, treatment settings, costs, and what real patients have experienced. Whether you’re a healthcare professional or someone navigating persistent depression, this article offers the clarity you need.
WHAT IS ESKETAMINE (SPRAVATO)?
A NEW APPROACH TO TREATING DEPRESSION
Esketamine is a chemical derivative of ketamine. While traditional ketamine is a racemic mixture, Esketamine is a more refined compound, offering stronger antidepressant effects at lower doses. Unlike oral antidepressants, which can take weeks to work, Esketamine starts working within hours.
Spravato is administered intranasally, which means it bypasses the digestive system and enters the bloodstream rapidly. Its mechanism targets the NMDA receptor, a part of the glutamate system that plays a role in mood regulation and cognitive function.
WHY IT MATTERS FOR TREATMENT-RESISTANT DEPRESSION
Patients with TRD have often tried multiple medications and therapies with little or no success. Esketamine provides:
- Rapid symptom relief
- A new pathway for treating depression
- Better outcomes when combined with talk therapy and oral antidepressants
IS SPRAVATO APPROVED IN NORWAY?
REGULATORY STATUS
Esketamine has been approved by the European Medicines Agency (EMA) since 2019 and is recognized under the Norwegian Medicines Agency (Statens legemiddelverk). However, access in Norway is limited to specific use cases and must follow strict guidelines.
WHO CAN PRESCRIBE ESKETAMINE?
In Norway, only psychiatrists and specialized mental health clinics can prescribe and administer Spravato. The treatment must be supervised by trained staff due to the potential for dissociation, dizziness, or a rise in blood pressure.
HOW THE TREATMENT WORKS
IN-CLINIC SUPERVISION
Esketamine is never taken at home. Instead, patients visit a clinic where:
- A psychiatrist or nurse administers the nasal spray
- The patient remains under observation for at least two hours
- Vitals are checked regularly to ensure safety
- The patient is not allowed to drive for the rest of the day
DOSING SCHEDULE
Treatment usually begins with twice-weekly sessions for the first four weeks, followed by once-weekly or biweekly sessions depending on the patient’s response. It is always used in combination with an oral antidepressant.
ESKETAMINE VS. OTHER KETAMINE FORMS
| Form | Route | Speed of Action | Availability in Norway | Approved Use |
|---|---|---|---|---|
| Esketamine (Spravato) | Nasal spray | Fast (within hours) | Limited, by prescription | TRD only |
| IV Ketamine | Intravenous | Very fast | Private clinics only | Off-label for depression |
| Oral Ketamine | Lozenges | Moderate | Very limited use | Rare, off-label |
While IV and oral ketamine are used off-label, Spravato is the only ketamine-based medication officially approved for depression in Norway.
WHO IS ELIGIBLE FOR SPRAVATO?
CRITERIA FOR TREATMENT
Patients must meet strict eligibility guidelines:
- Diagnosis of major depressive disorder (MDD)
- Documented failure of at least two antidepressants
- No current substance abuse
- No history of psychosis
WHO SHOULD AVOID ESKETAMINE?
Not everyone is a suitable candidate. Patients with the following conditions should avoid Spravato:
- Uncontrolled hypertension
- History of brain aneurysm or stroke
- Active psychosis or schizophrenia
- Pregnancy or breastfeeding
BENEFITS OF NASAL SPRAY KETAMINE
RAPID SYMPTOM RELIEF
One of the most compelling features of Spravato is its fast onset of action. Many patients notice improvements in mood and energy levels within 24 hours of the first session.
ENHANCED EFFECTS WITH PSYCHOTHERAPY
Combining Spravato with talk therapy often leads to greater symptom improvement. Patients become more open and emotionally accessible after treatment, improving therapeutic outcomes.
IMPROVED FUNCTIONALITY
Patients frequently report:
- Better sleep
- Reduced suicidal ideation
- Higher motivation to engage in daily life
- Enhanced emotional clarity
POTENTIAL SIDE EFFECTS
As with any medication, there are risks. Side effects typically occur during or shortly after administration and may include:
- Dissociation or feeling “spaced out”
- Nausea
- Increased blood pressure
- Headache
- Anxiety or restlessness
Most side effects resolve within an hour or two, and patients are monitored until they return to baseline.
COST OF TREATMENT IN NORWAY
IS IT COVERED BY PUBLIC HEALTH INSURANCE?
Currently, Spravato is not reimbursed by HELFO (the Norwegian Health Economics Administration) in most cases. Some exceptions may exist under individual applications, especially if a psychiatrist justifies the need.
ESTIMATED COST IN PRIVATE SETTINGS
At private psychiatric clinics, the cost can range from:
- Initial assessment: NOK 1,500 – 2,000
- Each session: NOK 4,000 – 6,000
- Monthly treatment plan: NOK 16,000 – 24,000
While expensive, many patients find the cost worthwhile given the fast and transformative results.
PATIENT EXPERIENCES IN NORWAY
IDA’S STORY – TRONDHEIM, AGE 39
Ida had battled severe depression since her twenties. After two hospitalizations and several failed medications, her psychiatrist suggested Spravato.
“After my second session, I finally felt a shift. It was subtle but powerful. I stopped crying every day. I felt like I could breathe again.”
She now continues treatment monthly and has resumed part-time work.
MIKKEL’S STORY – OSLO, AGE 45
Mikkel had been on SSRIs for over 10 years with little benefit. His psychiatrist in Oslo offered Esketamine through a private clinic.
“I was skeptical, but it was the first thing that actually made me feel different. The world stopped looking grey.”
His sessions are now spaced out to every two weeks.
WHERE TO FIND SPRAVATO TREATMENT IN NORWAY
Esketamine is offered at select private mental health clinics and university-affiliated centers in:
- Oslo
- Bergen
- Trondheim
- Stavanger
If you are interested in Spravato, start by consulting your primary care doctor or psychiatrist, who can assess your eligibility and provide a referral.
SCIENTIFIC EVIDENCE BEHIND SPRAVATO
Clinical studies published in journals like JAMA Psychiatry and The Lancet confirm that Esketamine:
- Reduces depressive symptoms within 24 hours
- Shows significant benefit in reducing suicidal thoughts
- Works well in patients unresponsive to at least two antidepressants
A European study conducted in 2022 found that over 60% of participants with TRD experienced meaningful symptom reduction after four weeks of Esketamine treatment.
FUTURE OUTLOOK: EXPANDING ACCESS IN NORWAY
Though availability is still limited, mental health professionals across Norway are lobbying for wider access to Spravato through public health services. Clinical trials are ongoing at Norwegian universities, and several regional health authorities are evaluating integration.
With increasing demand and strong evidence, Esketamine may soon become more accessible to patients in both private and public healthcare settings.
CONCLUSION: SHOULD YOU CONSIDER SPRAVATO?
Esketamine (Spravato) offers a new frontier for treating depression—especially when traditional methods fail. While access in Norway is limited, eligible patients can find help at private clinics under psychiatric supervision. The nasal spray format, rapid relief, and scientific backing make it a promising option for those in need.
If you or someone you care about struggles with treatment-resistant depression, it may be time to explore Spravato as a next step. Speak with your psychiatrist, and make sure you’re receiving evidence-based care from a licensed provider.